Open Access
Issue
Parasite
Volume 30, 2023
Article Number 46
Number of page(s) 10
DOI https://doi.org/10.1051/parasite/2023047
Published online 02 November 2023
  1. Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, Lepczyk C, Lilly EL, McLeod R, Milcarsky J, Murphy CE, Su C, VanWormer E, Yolken R, Sizemore GC. 2019. The One Health approach to toxoplasmosis: Epidemiology, control, and prevention strategies. Ecohealth, 16(2), 378–390. [CrossRef] [PubMed] [Google Scholar]
  2. Aliberti J. 2005. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nature Reviews Immunology, 5(2), 162–170. [CrossRef] [PubMed] [Google Scholar]
  3. Attias M, Teixeira DE, Benchimol M, Vommaro RC, Crepaldi PH, De Souza W. 2020. The life-cycle of Toxoplasma gondii reviewed using animations. Parasites & Vectors, 13(1), 588. [CrossRef] [PubMed] [Google Scholar]
  4. Azadi Y, Ahmadpour E, Ahmadi A. 2020. Targeting strategies in therapeutic applications of toxoplasmosis: Recent advances in liposomal vaccine delivery systems. Current Drug Targets, 21(6), 541–558. [CrossRef] [PubMed] [Google Scholar]
  5. Ching XT, Fong MY, Lau YL. 2017. Evaluation of the protective effect of deoxyribonucleic acid vaccines encoding granule antigen 2 and 5 against acute toxoplasmosis in BALB/c Mice. American Journal of Tropical Medecine and Hygiene, 96(6), 1441–1447. [CrossRef] [PubMed] [Google Scholar]
  6. Corthesy B. 2013. Multi-faceted functions of secretory IgA at mucosal surfaces. Frontiers in Immunology, 4, 185. [CrossRef] [PubMed] [Google Scholar]
  7. Denkers EY, Gazzinelli RT. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clinical Microbiology Reviews, 11(4), 569–588. [CrossRef] [PubMed] [Google Scholar]
  8. Donaldson TM, Cassera MB, Ho MC, Zhan C, Merino EF, Evans GB, Tyler PC, Almo SC, Schramm VL, Kim K. 2014. Inhibition and structure of Toxoplasma gondii purine nucleoside phosphorylase. Eukaryotic Cell, 13(5), 572–579. [CrossRef] [PubMed] [Google Scholar]
  9. Dubey JP. 2005. Unexpected oocyst shedding by cats fed Toxoplasma gondii tachyzoites: in vivo stage conversion and strain variation. Veterinary Parasitology, 133(4), 289–298. [CrossRef] [PubMed] [Google Scholar]
  10. Feliciano-Alfonso JE, Munoz-Ortiz J, Marin-Noriega MA, Vargas-Villanueva A, Trivino-Blanco L, Carvajal-Saiz N, de-la-Torre A. 2021. Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis. Systematic Reviews, 10(1), 206. [CrossRef] [PubMed] [Google Scholar]
  11. Fox BA, Bzik DJ. 2015. Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection. Infection and Immunity, 83(5), 2148–2155. [CrossRef] [PubMed] [Google Scholar]
  12. Gesualdo L, Di Leo V, Coppo R. 2021. The mucosal immune system and IgA nephropathy. Seminars in Immunopathology, 43(5), 657–668. [CrossRef] [PubMed] [Google Scholar]
  13. Igarashi M, Zulpo DL, Cunha IA, Barros LD, Pereira VF, Taroda A, Navarro IT, Vidotto O, Vidotto MC, Jenkins MC, Garcia JL. 2010. Toxoplasma gondii: humoral and cellular immune response of BALB/c mice immunized via intranasal route with rTgROP2. Revista Brasileira de Parasitologia Veterinaria, 19(4), 210–216. [CrossRef] [Google Scholar]
  14. Iltzsch MH. 1993. Pyrimidine salvage pathways in Toxoplasma gondii. Journal of Eukaryotic Microbiology, 40(1), 24–28. [CrossRef] [PubMed] [Google Scholar]
  15. Kang HJ, Chu KB, Kim MJ, Lee SH, Park H, Jin H, Moon EK, Quan FS. 2021. Protective immunity induced by CpG ODN-adjuvanted virus-like particles containing Toxoplasma gondii proteins. Parasite Immunology, 43(1), e12799. [CrossRef] [PubMed] [Google Scholar]
  16. Li Y, Jin L, Chen T. 2020. The effects of secretory IgA in the mucosal immune system. Biomed Research International, 2020, 2032057. [PubMed] [Google Scholar]
  17. Liu F, Wu M, Wang J, Wen H, An R, Cai H, Yu L, Shen J, Chen L, Du J. 2021. Protective effect against toxoplasmosis in BALB/c mice vaccinated with recombinant Toxoplasma gondii MIF, CDPK3, and 14-3-3 protein cocktail vaccine. Frontiers in Immunology, 12, 755792. [CrossRef] [PubMed] [Google Scholar]
  18. Liu Z, Yin L, Li Y, Yuan F, Zhang X, Ma J, Liu H, Wang Y, Zheng K, Cao J. 2016. Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice. BMC Immunology, 17(1), 37. [CrossRef] [PubMed] [Google Scholar]
  19. Liu Z, Yuan F, Yang Y, Yin L, Liu Y, Wang Y, Zheng K, Cao J. 2016. Partial protective immunity against toxoplasmosis in mice elicited by recombinant Toxoplasma gondii malate dehydrogenase. Vaccine, 34(7), 989–994. [CrossRef] [PubMed] [Google Scholar]
  20. Ma GY, Zhang JZ, Yin GR, Zhang JH, Meng XL, Zhao F. 2009. Toxoplasma gondii: proteomic analysis of antigenicity of soluble tachyzoite antigen. Experimental Parasitology, 122(1), 41–46. [CrossRef] [PubMed] [Google Scholar]
  21. Mahdi Ghahari SM, Ajami A, Sadeghizadeh M, Esmaeili Rastaghi AR, Mahdavi M. 2022. Nanocurcumin as an adjuvant in killed Toxoplasma gondii vaccine formulation: An experience in BALB/c mice. Experimental Parasitology, 243, 108404. [CrossRef] [PubMed] [Google Scholar]
  22. Martorelli Di Genova B, Knoll LJ. 2020. Comparisons of the sexual cycles for the coccidian parasites Eimeria and Toxoplasma. Frontiers in Cellular and Infection Microbiology, 10, 604897. [CrossRef] [PubMed] [Google Scholar]
  23. Milne G, Webster JP, Walker M. 2020. Toxoplasma gondii: An underestimated threat? Trends in Parasitology, 36(12), 959–969. [CrossRef] [PubMed] [Google Scholar]
  24. Nagineni CN, Pardhasaradhi K, Martins MC, Detrick B, Hooks JJ. 1996. Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infection and Immunity, 64(10), 4188–4196. [CrossRef] [PubMed] [Google Scholar]
  25. Nguyen TT, Kamyingkird K, Phimpraphai W, Inpankaew T. 2022. Viability of Toxoplasma gondii tachyzoites in different conditions for parasite transportation. Veterinary World, 15(1), 198–204. [CrossRef] [PubMed] [Google Scholar]
  26. Nguyen TT, Kengradomkij C, Inpankaew T. 2021. Detection of antibodies to Toxoplasma gondii among owned dogs in Cambodia. Food and Waterborne Parasitology, 22, e00103. [CrossRef] [PubMed] [Google Scholar]
  27. O’Hagan DT, Valiante NM. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Reviews Drug Discovery, 2(9), 727–735. [CrossRef] [PubMed] [Google Scholar]
  28. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annual Review of Immunology, 29, 71–109. [CrossRef] [PubMed] [Google Scholar]
  29. Penarete-Vargas DM, Mevelec MN, Dion S, Seche E, Dimier-Poisson I, Fandeur T. 2010. Protection against lethal Neospora caninum infection in mice induced by heterologous vaccination with a mic1 mic3 knockout Toxoplasma gondii strain. Infection and Immunity, 78(2), 651–660. [CrossRef] [PubMed] [Google Scholar]
  30. Rahimi MT, Mahdavi SA, Javadian B, Rezaei R, Moosazadeh M, Khademlou M, Seyedpour SH, Syadatpanah A. 2015. High seroprevalence of Toxoplasma gondii antibody in HIV/AIDS individuals from North of Iran. Iranian Journal of Parasitology, 10(4), 584–589. [PubMed] [Google Scholar]
  31. Rashid I, Moire N, Heraut B, Dimier-Poisson I, Mevelec MN. 2017. Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route. Medical Microbiology and Immunology, 206(1), 53–62. [CrossRef] [PubMed] [Google Scholar]
  32. Saijo-Hamano Y, Sherif AA, Pradipta A, Sasai M, Sakai N, Sakihama Y, Yamamoto M, Standley DM, Nitta R. 2022. Structural basis of membrane recognition of Toxoplasma gondii vacuole by Irgb6. Life Science Alliance, 5(1), e202101149. [CrossRef] [PubMed] [Google Scholar]
  33. Sasai M, Yamamoto M. 2019. Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection. Experimental amd Molecular Medicine, 51(12), 1–10. [CrossRef] [PubMed] [Google Scholar]
  34. Su HC, Orange JS, Fast LD, Chan AT, Simpson SJ, Terhorst C, Biron CA. 1994. IL-2-dependent NK cell responses discovered in virus-infected beta 2-microglobulin-deficient mice. Journal of Immunology, 153(12), 5674–5681. [CrossRef] [PubMed] [Google Scholar]
  35. Suzuki Y. 2002. Host resistance in the brain against Toxoplasma gondii. Journal of Infectious Disease, 185(Suppl 1), S58–S65. [CrossRef] [PubMed] [Google Scholar]
  36. Tian X, Wang M, Xie T, Wan G, Sun H, Mei X, Zhang Z, Li X, Wang S. 2022. A recombinant protein vaccine encoding Toxoplasma gondii Cyst wall 2 (dense granule protein 47) provides partial protection against acute and chronic T. gondii infection in BALB/c mice. Acta Tropica, 232, 106514. [CrossRef] [PubMed] [Google Scholar]
  37. Tong WH, Pavey C, O’Handley R, Vyas A. 2021. Behavioral biology of Toxoplasma gondii infection. Parasites & Vectors, 14(1), 77. [CrossRef] [PubMed] [Google Scholar]
  38. Wang HL, Li YQ, Yin LT, Meng XL, Guo M, Zhang JH, Liu HL, Liu JJ, Yin GR. 2013. Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis. PLoS One, 8(8), e70884. [CrossRef] [PubMed] [Google Scholar]
  39. Wang HL, Pang M, Yin LT, Zhang JH, Meng XL, Yu BF, Guo R, Bai JZ, Zheng GP, Yin GR. 2014. Intranasal immunisation of the recombinant Toxoplasma gondii receptor for activated C kinase 1 partly protects mice against T. gondii infection. Acta Tropica, 137, 58–66. [CrossRef] [PubMed] [Google Scholar]
  40. Wang HL, Wang YJ, Pei YJ, Bai JZ, Yin LT, Guo R, Yin GR. 2016. DNA vaccination with a gene encoding Toxoplasma gondii Rhoptry Protein 17 induces partial protective immunity against lethal challenge in mice. Parasite, 23, 4. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  41. Wang HL, Wen LM, Pei YJ, Wang F, Yin LT, Bai JZ, Guo R, Wang CF, Yin GR. 2016. Recombinant Toxoplasma gondii phosphoglycerate mutase 2 confers protective immunity against toxoplasmosis in BALB/c mice. Parasite, 23, 12. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  42. Wang HL, Zhang TE, Yin LT, Pang M, Guan L, Liu HL, Zhang JH, Meng XL, Bai JZ, Zheng GP, Yin GR. 2014. Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii rhoptry protein 17 against toxoplasmosis in mice. PLoS One, 9(9), e108377. [CrossRef] [PubMed] [Google Scholar]
  43. Wilhelm CL, Yarovinsky F. 2014. Apicomplexan infections in the gut. Parasite Immunology, 36(9), 409–420. [CrossRef] [PubMed] [Google Scholar]
  44. Yin LT, Hao HX, Wang HL, Zhang JH, Meng XL, Yin GR. 2013. Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis. PLoS One, 8(12), e82765. [CrossRef] [PubMed] [Google Scholar]
  45. Yin LT, Zhu JJ, Li RH, Wang HL, Li YQ, Yin GR. 2014. Gene-cloning, expression and immunoreactivity detection of Toxoplasma gondii uridine phosphorylase. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, 32(1), 24–28. [PubMed] [Google Scholar]
  46. Yoon KW, Chu KB, Kang HJ, Kim MJ, Eom GD, Lee SH, Moon EK, Quan FS. 2021. mucosal administration of recombinant baculovirus displaying Toxoplasma gondii ROP4 confers protection against T. gondii challenge infection in mice. Frontiers in Cellular and Infection. Microbiology, 11, 735191. [Google Scholar]
  47. Zhang TE, Yin LT, Li RH, Wang HL, Meng XL, Yin GR. 2015. Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice. Parasites & Vectors, 8, 15. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.